News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
POLICY
China to Exempt Import Tariffs on 61 Active Pharmaceutical Ingredients for Anticancer and Rare Disease Drugs
China will apply interim import tax rates that are lower than most-favored-nation tariffs on 883 kinds of goods from Jan. 1, 2021, according to the 2021 Tariff Adjustment Plan issued by the Customs Tariff Commission of the State Council on Dec. 23, 2020.
Mar 08, 2021
POLICY
Chinese Market Becomes More Intense for Antidiabetic Drugs
China's fourth round of national centralized drug procurement has begun, according to the Jinfu Chen, deputy head of the National Healthcare Security Administration in Beijing on Jan. 29, 2021. This time five new diabetes medications are included in the procurement list. They are empagliflozin, canagliflozin, repaglinide, nateglinide, and gliclazide.
Mar 08, 2021
REGULATION
China Requires Drug Market Authorization Holders to Submit Annual Report
On Dec. 10, 2020, the National Medical Products Administration (NMPA) published the drafts of Administrative Provisions of Annual Drug Reports and Template for the Annual Drug Report, asking for public consultation before Dec. 22, 2020.
Mar 08, 2021
REGULATION
Most Popular
- [Updated] China Issues the 2020 Edition of Chinese Pharmacopoeia
- Monthly Report: New Drug Approvals in China | March 2023
- What's New About China's 8th Volume-based Procurement (VBP) of Drugs
- Monthly Recap: China Pharmaceutical Regulatory Updates | March 2023
- For Injectable Complex Generics, China Has Special CMC Requirements
